Delving into the Latest Updates on Ildong Holdings Co., Ltd. with Synapse

Overview

Tags

Congenital Disorders

Digestive System Disorders

Neoplasms

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Chemical drugs	2

Ildong Holdings Co., Ltd. (KOSE:A000230) agreed to acquire an additional 13% stake in Il Dong Bio Science Co., Ltd. for KRW13 billion on October 2, 2024. A cash consideration of KRW 13 billion will be paid by Ildong Holdings Co., Ltd. As part of consideration, KRW 13 billion is paid towards common equity of Il Dong Bio Science Co., Ltd. Upon completion, Ildong Holdings Co., Ltd. will own 63.10% stake in Il Dong Bio Science Co., Ltd.

For the period ending December 31, 2023, Il Dong Bio Science Co., Ltd. reported total revenue of KRW 638.45 billion and net loss of KRW 118.79 billion. As of December 31, 2023, Il Dong Bio Science Co., Ltd. reported total debt of KRW 707.1 billion, total assets of KRW 876 billion and total common equity of KRW 169.9 billion.

The expected completion of the transaction is October 2, 2024.

AcquisitionFinancial Statement

100 Deals associated with Ildong Holdings Co., Ltd.

Login to view more data

100 Translational Medicine associated with Ildong Holdings Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Other

Login to view more data